| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-08-05 | La Jolla Pharmaceutical (USA - CA) The Indiana University Research and Technology Corporation (IURTC) (USA - IN) The University of Alabama at Birmingham (UAB) (USA - AL) | LJPC-30Sa, LJPC-30Sb | licensing |
Infectious diseases - Genetic diseases - Rare diseases | Licensing agreement | |
| 2015-08-05 | Halozyme Therapeutics (USA - CA) | nomination |
Nomination | |||
| 2015-08-05 | Acucela (USA - MA) | nomination |
Ophtalmological diseases | Nomination | ||
| 2015-08-04 | Capricor Therapeutics (USA - CA) | nomination |
Cardiovascular diseases | Nomination | ||
| 2015-08-04 | Progenics Pharmaceuticals (USA - NY) Johns Hopkins University (USA - MD) | [18F]DCFPyL | prostate cancer | licensing |
Cancer - Oncology - Diagnostic | Licensing agreement |
| 2015-08-04 | Allena Pharmaceuticals (USA - MA) | Rare diseases - Metabolic diseases | Nomination | |||
| 2015-08-04 | Curevac (Germany) the Bill & Melinda Gates Foundation (USA) | prophylactic vaccine to protect against respiratory syncytial virus (RSV) | respiratory syncytial virus (RSV) | development |
Infectious diseases | Development agreement |
| 2015-08-04 | Minerva Biotechnologies (USA - MA) iPS Academia Japan (Japan) | induced Pluripotent Stem (iPS) cells patent portfolio | licensing |
Cancer - Oncology - Technology - Services | Licensing agreement | |
| 2015-08-04 | G7 Therapeutics (Germany) Morphosys (Switzerland) | antibody therapeutics targeting G protein-coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins such as ion channels | R&D |
R&D agreement | ||
| 2015-08-04 | Eli Lilly (USA - IN) University of California, San Diego (USA - CA) | solanezumab | Alzheimer\'s disease | termination of the agreement |
Neurodegenerative diseases | Termination of the agreement |
| 2015-08-03 | Pfizer (USA - NY) Synthon (The Netherlands) | glatiramer acetate | relapsing remitting multiple sclerosis | commercialisation |
Neurodegenerative diseases | Commercialisation agreement |
| 2015-08-03 | Sorrento Therapeutics (USA - CA) Mabtech (China) | multiple prespecified and undisclosed biosimilar or biobetter monoclonal antibodies | licensing development commercialisation |
Autoimmune diseases | Establishment of a new subsidiary in the EU | |
| 2015-08-03 | Cell Therapy Catapult (UK) Cellular Therapeutics (UK) | engineered T cell treatment | hematological cancers including acute myeloid leukaemia and myelodysplastic syndrome | services contract |
Cancer - Oncology - Technology - Services | Services contract |
| 2015-08-03 | Formula Pharmaceuticals (USA - PA) Max Delbrück Center for Molecular Medicine (Germany) | Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) immunotherapies | licensing collaboration |
Autoimmune diseases - Cancer - Oncology | Licensing agreement | |
| 2015-07-31 | TiGenix (Belgium) | resignation |
Resignation | |||
| 2015-07-31 | Eisai (Japan) Halozyme Therapeutics (USA - CA) | PEGPH20 and eribulin (Halaven®) | first line HER2-negative metastatic breast cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-07-30 | AstraZeneca (UK) Charles River Laboratories International (USA) | regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics) studie | services |
Technology - Services | Clinical research agreement | |
| 2015-07-30 | MorphoSys (Germany) Heptares Therapeutics (UK), a subsidiary of Sosei Group (Japan) | novel antibody therapeutics targeting G protein-coupled receptors (GPCRs) | R&D |
Milestone | ||
| 2015-07-30 | Ligand Pharmaceuticals (USA - CA) Sanofi (France) | Captisol-enabled SAR-125844 | solid tumors | licensing supply |
Cancer - Oncology | Licensing agreement |
| 2015-07-30 | IBM (USA - NY) CVS Health (USA - RI) | management services for patients with chronic disease | chronic diseases including hypertension, heart disease, diabetes, and obesity | collaboration |
Technology - Services - Diagnostic - Medical imaging - Cardiovascular diseases - Metabolic diseases | Collaboration agreement |
